Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

regimen

TRAS(MNT)

Cancer Type
Gastrointestinal, Esophagus, Gastric Stomach
Intent
Palliative
Regimen Category
Evidence-Informed
Funding Program
New Drug Funding Program Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
Drugs Used
trastuzumab

Regimen Monograph

Dec 2024
View Monograph

Patient Info Sheet

Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.

Last Updated: July 27, 2026

The information on this website is intended for informational purposes only and is not a substitute for medical advice. Always consult your health care provider if you have questions or concerns. The use of the information on this website does not create a physician-patient relationship between Ontario Health and you.
Ontario Health is committed to ensuring accessible services and communications to individuals with disabilities. To receive any information on this website in an alternate format, please contact Ontario Health’s Communications Department at: 1-877-280-8538,TTY 1-800-855-0511, or by email at info@ontariohealth.ca.

The province of Ontario Logo
© Ontario Health 2025